RxDoctor Payments Data

Matthew Miles, MD

Pulmonary Disease · Winston Salem, NCNPI 1316954522

Payments from drug & device makers

$1,766in general payments, 2019–2025

Across 10 payments — averaging $176.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • Pulmonx Corporation$142
  • Bayer$125
  • GSK$120
  • Medtronic$92
  • AstraZeneca$29
  • plus $27 from 2 others

What the payments were for

  • Consulting fees$1,35577%
  • Food & beverage$41123%

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,766 in reported general payments places this provider in the 50th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$72,364
Medicare patients
349
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate41$626,998
Stiolto RespimatTiotropium Br/Olodaterol Hcl41$37,934
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$35,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$33,365
Spiriva HandihalerTiotropium Bromide42$30,779
Spiriva RespimatTiotropium Bromide26$22,730
SymbicortBudesonide/Formoterol Fumarate73$19,541
Advair HfaFluticasone Propion/Salmeterol27$17,416
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$15,587
Breo ElliptaFluticasone/Vilanterol24$12,797
Sirolimus19$12,161
Combivent RespimatIpratropium/Albuterol Sulfate12$5,685
Arnuity ElliptaFluticasone Furoate18$4,468
Albuterol Sulfate HfaAlbuterol Sulfate78$2,221
Ventolin HfaAlbuterol Sulfate28$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$120$66,21792 claims
AstraZenecaBreztri Aerosphere, Symbicort$29$55,390120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →